Integrated Population Program for Diabetic Kidney Disease

Status Completed

Clinical Trial Summary

This study will build a population management system Simultaneous risk factor control using Telehealth to slOw Progression of Diabetic Kidney Disease STOP-DKD Application STOP-DKD APP and conduct a 6-month controlled trial to compare reduction of blood pressure. In addition, the study will evaluate the feasibility of future large-scale intervention to slow diabetic kidney disease (DKD) DKD progression.

Aim 1: Identify patients with moderate DKD and uncontrolled hypertension (HTN) using existing electronic health record data in an integrated data warehouse (Southeastern Diabetes Initiative- SEDI) to screen all patients within SEDI.

Aim 2: Implement an intervention designed to slow progression of DKD and treat associated conditions in a high-risk population with moderate DKD and uncontrolled HTN using the STOP-DKD APP

- Primary Outcome: Test the hypothesis that patients who receive the intervention will have greater improvements in blood pressure as compared to a control group after 6 months

- Secondary Outcomes: Exploratory analyses to determine whether patients who receive the intervention will have less progression (defined as a smaller decrease in kidney function), and improved behaviors that affect HTN control and cardiovascular risk (medication adherence, diet, physical activity, and weight control) as compared to a control group after 6 months

Aim 3: Evaluate the STOP-DKD APP Study to guide large-scale implementation & dissemination

- Impact Evaluation: Assess the potential population impact of our intervention using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework

- Economic Evaluation: Conduct an economic evaluation using the Archimedes Model by estimating projected costs and quality-adjusted life-years

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02418091
Study type	Interventional
Source	Duke University
Contact
Status	Completed
Phase	N/A
Start date	March 2015
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06006689` - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)	Phase 2
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed	`NCT05086549` - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting	`NCT05008276` - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed	`NCT02276196` - Effect of LIXIsenatide on the Renal System	Phase 4
Not yet recruiting	`NCT06120569` - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients	N/A
Completed	`NCT02545049` - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease	Phase 3
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting	`NCT06176599` - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis	N/A
Recruiting	`NCT03716401` - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Completed	`NCT01377688` - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes	N/A
Active, not recruiting	`NCT05514548` - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease	Phase 2
Recruiting	`NCT05507892` - Renal Mechanism of SGLT2 Inhibition	Phase 2
Not yet recruiting	`NCT05514184` - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease	N/A
Not yet recruiting	`NCT06049550` - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Active, not recruiting	`NCT04589351` - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe	Phase 3
Active, not recruiting	`NCT04531163` - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy	Phase 2/Phase 3
Active, not recruiting	`NCT03620773` - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes	Phase 1/Phase 2
Suspended	`NCT01878045` - Mechanisms of Diabetic Kidney Disease in American Indians

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Integrated Population Program for Diabetic Kidney Disease — STOP-DKD APP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms